Document:

<PAGE>
                                                                   Exhibit 4.20

EXECUTION COPY

                             DATE: 27TH JANUARY 2003

                             ELAN CORPORATION, PLC.
                        ELAN PHARMA INTERNATIONAL LIMITED
                        ELAN INTERNATIONAL SERVICES, LTD.
                           ELAN PHARMACEUTICALS, INC.
                              MONKSLAND HOLDINGS BV
                                       AND
                             AMARIN CORPORATION PLC.

                                MASTER AGREEMENT
<PAGE>
                                      INDEX

1.             DEFINITIONS AND INTERPRETATION.............................1

2.             THE AMENDMENTS.............................................3

3.             REFINANCING................................................3

4.             ASSET SALES................................................4

5.             USE OF PROCEEDS OF ASSET SALES.............................4

6.             USE OF PROCEEDS OF FURTHER FINANCING.......................6

7.             INVESTOR RELATIONS PROGRAM.................................6

8.             REPRESENTATIONS AND WARRANTIES.............................6

9.             MISCELLANEOUS..............................................8

SCHEDULE 1     EXISTING AGREEMENTS AND AMENDMENTS........................12

SCHEDULE 2     REFINANCING...............................................13
<PAGE>
THIS AGREEMENT is made the 27th January 2003

BETWEEN:

(1)   ELAN CORPORATION, PLC., a public limited company incorporated in the
      Republic of Ireland, whose registered office is at Lincoln House,
      Lincoln Place, Dublin 2, Ireland ("ELAN CORP")

(2)   ELAN PHARMA INTERNATIONAL LIMITED, a company incorporated in the Republic
      of Ireland, whose registered office is at WIL House, Shannon Business
      Park, Shannon, Co Clare, Ireland ("EPIL")

(3)   ELAN INTERNATIONAL SERVICES, LTD., a Bermuda exempted limited
      liability company incorporated under the laws of Bermuda and having
      its registered office at Clarendon House, 2 Church Street, Hamilton,
      Bermuda ("EIS")

(4)   ELAN PHARMACEUTICALS, INC., a corporation duly organized and
      existing under the applicable laws of the State of Delaware, having
      a principal place of business in South San Francisco, California
      ("EP INC")

(5)   MONKSLAND HOLDINGS BV, a private company limited by shares incorporated in
      the Netherlands under registered number 33265127, whose registered office
      is at Amsteldijk 166, 1079 Amsterdam, Netherlands ("MONKSLAND")

(6)   AMARIN CORPORATION PLC, a company incorporated in England and Wales
      (registered no. 002353920), whose registered office is 7 Curzon
      Street, London, W1J 5HG England ("AMARIN")

WHEREAS:

(A)   Amarin is a party to each of the agreements listed in Part A of Schedule 1
      (together the "EXISTING AGREEMENTS"). The other parties hereto are also
      parties to certain of the Existing Agreements as set forth in Part A of
      Schedule 1.

(B) Simultaneously herewith, Amarin has undertaken the Refinancing.

(C)   Amarin wishes to restructure its relationship with Elan and accordingly
      the parties have agreed to do so upon the terms set out in this Agreement
      and in the Amendments (as defined below).

NOW IT IS AGREED in consideration of the mutual promises and undertakings set
out herein as follows:

1.    DEFINITIONS AND INTERPRETATION

1.1.  Definitions:

      "ADR" shall mean the American Depositary Receipts of Amarin representing
      Amarin's American Depositary Shares ("ADSS"), each of which currently
      represents one ordinary share of L1 in the capital of the Amarin and as
      are traded on the Nasdaq National Market under the symbol "AMRN".

      "AFFILIATE" shall mean any corporation or entity controlling, controlled
      by or under the common control of Elan or Amarin or any third party, as
      the case may be. For the purpose of this definition, "control" shall mean
      direct or indirect ownership of fifty percent (50%) or more of the stock
      or shares entitled to vote for the election of directors.

                                     Page 1
<PAGE>
      "THIS AGREEMENT" shall mean this agreement and shall include the Recitals
      and Schedules hereto.

      "AMENDMENTS" shall mean each of the agreed form documents listed in Part
      B of Schedule 1 and "AMENDMENT" shall have a corresponding meaning.

      "CARNRICK AGREEMENT" shall mean the agreement referred to as number (3)
      of Part A of Schedule 1, as varied.

      "ELAN" shall mean Elan Corp, EPIL, EIS, EP Inc and/or Monksland as the
      context requires.

      "FURTHER EQUITY FINANCING" shall mean all and any equity financing by
      Amarin or any Affiliate, including by the issue of shares of any class,
      warrants, debt convertible into equity and/or the grant of the right to
      receive or to subscribe for shares of any class, but not including the
      Refinancing.

      "LEGACY SALE" shall mean the sale to one or more independent third
      parties of all or substantially all of the assets of Amarin and/or its
      Affiliates relating to all or substantially all of the following
      products/product lines: Motofen, Capital & Codeine, Nohalist and the
      Bontril and Phrenilin families of products.

      "LOAN AGREEMENT" shall mean the agreement referred to as number (1) of
      Part A of Schedule 1, as varied and as further varied by the relevant
      Amendment.

      "NET PROCEEDS" means in relation to (a) the Refinancing or (b) the Legacy
      Sale and/or Swedish sale or (c) Further Equity Financing; the gross
      amount received by Amarin less customary expenses properly incurred or
      reasonably expected to be incurred by Amarin in connection with the
      conclusion of such transaction (including bankers', brokers, legal and
      accounting fees, printing fees, stamp duty, stamp duty reserve tax, ADR
      issuance fees and NASDAQ fees related to the issuance of ADRs, the
      registration of shares and/or the listing of ADRs, and fees of the U.S.
      Securities and Exchange Commission related to the registration of shares
      and/or ADRs, but for the avoidance of doubt not including interest,
      repayment of principal, dividends or redemption of capital).

      "PERMAX AGREEMENT" shall mean the agreement referred to as number (2) of
      Part A of Schedule 1, as varied by the relevant Amendment.

      "PPM" shall mean Amarin's Amended Private Placement Memorandum dated 10th
      December 2002, a copy of which has been previously supplied to Elan
      (marked "draft"), as updated by a letter of 17 January 2003.

      "REFINANCING" shall mean the transaction described in Schedule 2.

      "SWEDISH SALE" shall mean the sale to an independent third party of (a)
      all or substantially all the shares in Amarin's Affiliate Amarin
      Development AB, Malmo, Sweden ("AMARIN AB") or (b) all or substantially
      all of the assets of Amarin AB.

      "ZELAPAR AGREEMENT" shall mean the agreement referred to as number (4) of
      Part A of Schedule 1, as varied and as further varied by the relevant
      Amendment.

      "$" and "US$" shall mean United States dollars.

1.2.  Interpretation:

In this Agreement:

                                     Page 2
<PAGE>
      1.2.1 the singular includes the plural and vice versa; references to words
            in one gender include references to the other genders; and
            references to natural persons includes corporate bodies,
            partnerships and vice versa;

      1.2.2 any reference to a Clause or Schedule, unless otherwise specifically
            provided, is to a Clause or Schedule of or to this Agreement;

      1.2.3 the headings in this Agreement are inserted for convenience only and
            do not affect its construction or interpretation;

      1.2.4 the expressions "include", "includes", "including", "in particular"
            and similar expressions shall be construed without limitation.

2.    THE AMENDMENTS

Immediately after execution of this Agreement, the respective parties to each of
the Amendments shall execute and deliver each of the Amendments to the other
parties thereto.

3.    REFINANCING

3.1.  Limited Waiver (Permax):

For the purposes of the Permax Agreement, EP Inc agrees that Amarin shall not,
as a result of the Refinancing, be obliged to apply any part of the proceeds of
the Refinancing in the manner set out in Section 3.01(d) of the Permax
Agreement, but shall instead apply such proceeds in the manner set out in this
Agreement.

3.2.  Preference Shares Conversion Rate Unchanged:

Subject to Amarin complying with the conditions set out in this Agreement EIS
hereby agrees with Amarin that the Refinancing shall for the purposes of Section
3.5 of the Appendix to Amarin's articles of association, as amended, not result
in any adjustment to the Preference Conversion Rate (as defined therein).

3.3.  Use of Proceeds:

Amarin and Elan acknowledge and agree that as of the date of this Agreement, the
following amounts (inter alia) are due to Elan:

(a)   US$2,357,038 (two million three hundred and fifty seventy thousand and
      thirty eight dollars) as interest outstanding under the Loan Agreement up
      to and including 31 December 2002, which amount does not include Default
      Interest (as defined therein);

(b)   US$8,641,387 (eight million six hundred and forty one thousand three
      hundred and eighty seven dollars) under the Permax Agreement comprising:

      (i)   US$6,207,476 (six million two hundred and seven thousand four
            hundred and seventy six dollars) in respect of Permax inventory;

      (ii)  US$2,500,000 (two million five hundred thousand dollars) due as a
            Divestiture Payment (as defined in the Permax Agreement) relating to
            the three months ending 30 September 2002;

      (iii) US$933,911 (nine hundred and thirty three thousand nine hundred and
            eleven dollars) due as a Royalty Payment (as defined in the Permax
            Agreement) for the nine months ending 30 September 2002; and

                                     Page 3
<PAGE>
      (iv)  a credit of US$1,000,000 (one million dollars) due from EP Inc to
            Amarin as a Royalty Purchase Payment (as defined in the Permax
            Agreement) in respect of the three months ending 30 September 2002.

Upon closing of the Refinancing and receipt by Amarin of the Amendments executed
by Elan Amarin shall apply certain of its cash reserves and certain of the Net
Proceeds of the Refinancing first to the discharge of the foregoing amounts and
at such time Amarin shall pay:

      3.3.1 US$2,357,038 (two million three hundred and fifty seven thousand and
            thirty eight dollars) to EPIL in complete discharge of the amount
            referred to in paragraph (a) above; and

      3.3.2 US$8,641,387(eight million six hundred and forty one thousand three
            hundred and eighty seven dollars) to EP Inc in discharge of the
            amount referred to in paragraph (b) above.

4.    ASSET SALES

4.1.  Subject to the fiduciary obligations of the Board of Directors, Amarin
      shall use all its commercial best efforts to effect for upfront cash
      consideration the Legacy Sale and the Swedish Sale, in each case for a
      reasonable sum, as expeditiously as is reasonably practicable after the
      date of this Agreement.

4.2.  Amarin shall notify Elan as soon as is reasonably practicable following
      the Legacy Sale and the Swedish Sale of the fact of, gross proceeds and
      Net Proceeds of the Legacy Sale and the Swedish Sale.

4.3.  Not later than the last day of each calendar month, commencing February
      2003, Amarin shall provide to Elan:

      4.3.1 a summary update of the status of the Legacy Sale and the Swedish
            Sale; and

      4.3.2 certification from a company officer (a) stating that the
            requirements of this Clause 4 have been complied with and (b)
            outlining in reasonable detail the steps taken by Amarin during that
            month to effect the Legacy Sale and the Swedish Sale.

      The obligation to provide updates and/or certification shall cease
      following the completion of the Legacy Sale and the Swedish Sale and the
      application of the Net Proceeds of the same in accordance with this
      Agreement.

5.    USE OF PROCEEDS OF ASSET SALES

5.1.  Payments:

Subject to Clause 5.2, Amarin shall apply the entire Net Proceeds of the Legacy
Sale and the Swedish Sale as follows:

      5.1.1 First, in paying to EPIL the non-refundable sum of US$5,000,000
            (five million dollars);

      5.1.2 Next, in paying to EP Inc the balance of the Total Divestiture
            Amount (as defined in the Permax Agreement) then outstanding, in
            partial or total discharge of that part of the Total Divestiture
            Amount then undischarged;

                                     Page 4
<PAGE>
      5.1.3 Next, in prepaying to EP Inc the Deferred Payment (as defined in the
            Carnrick Agreement), in partial or total discharge of that part of
            the Deferred Payment of US$6,500,000 (six and a half million
            dollars) then undischarged;

      5.1.4 Next, in prepaying to EPIL the Loan (as defined in the Loan
            Agreement) which is outstanding;

      5.1.5 Next, in discharging any amounts then due to Elan Corp and/or any of
            its Affiliates, howsoever arising;

      5.1.6 Finally, for such other purposes as Amarin in its absolute
            discretion may think fit.

Subject to Clause 5.2, such payments to Elan shall be made within 10 (ten) days
of the closing of each of the Legacy Sale and the Swedish Sale.

5.2.  Partial Right to Defer:

After having applied the first $35,000,000 (thirty five million dollars) of the
Net Proceeds of the Legacy Sale and the Swedish Sale in the manner provided in
Clause 5.1, Amarin may at its option elect, by written notice to Elan, to apply
not more than one half of the balance of such Net Proceeds after payment of the
said $35,000,000 ("RETAINED PROCEEDS") for such purposes as it sees fit. In such
event, Amarin shall within 6 (six) months of the closing of the Legacy Sale
and/or the Swedish Sale, as the case may be, apply an amount equal to the
Retained Proceeds in the manner provided in Clauses 5.1.1 to 5.1.6.

Nothing in this Clause 5.2 shall affect any right of Elan, or of any other
Affiliate of Elan Corp, other than those set out in Clause 5.1.

5.3.  Right to Amend:

Elan shall be entitled, in its sole discretion, to amend the order in which the
Net Proceeds of the Legacy Sale and/or the Swedish Sale shall be applied, as
between the uses specified in Clauses 5.1.1 to 5.1.5 inclusive. Such amendment
will become effective upon receipt by Amarin of a written notice by Elan at any
time or times but for the avoidance of doubt any such notice shall not have
retrospective effect in respect of any payments previously made by Amarin to
either of EPIL or EP Inc. in accordance with Clause 5.1.

5.4.  Credit Against First Zelapar Milestone:

Amarin shall be entitled to recover such amount as it has paid to EPIL under
Clause 5.1.1 as a credit against the milestone of US$17,500,000 payable under
Section 7.2(a) of the Zelapar Agreement (as varied by the relevant Amendment).

For the avoidance of doubt and without prejudice to the generality of Clause
5.6, in the event that Amarin does not exercise the Option (as defined in the
Zelapar Agreement), or the amount under Section 7.2(a) of the Zelapar Agreement
otherwise does not become payable for any reason, Amarin shall not be entitled
to any refund of amounts paid under Clause 5.1.1.

5.5.  Effect on Permax Agreement:

Any payment made by Amarin to EP Inc under Clause 5.1.2 shall be credited first
against the last payments in time under Section 3.01(c) of the Permax Agreement
with the intention and effect that the Net Proceeds shall be used to accelerate
the payments due to EP Inc.

5.6.  No Refund:

                                     Page 5
<PAGE>
Payments made to Elan under this Clause 5 shall be non-refundable and shall not
be subject to any future performance obligations of Elan to Amarin or applicable
against any future services provided from Elan to Amarin.

6.    USE OF PROCEEDS OF FURTHER FINANCING

6.1.  Application of Proceeds:

In the event that at any time or times prior to the payment in full of:

      (a)   the Total Divestiture Amount (as defined in the Permax Agreement);

      (b)   the Deferred Payment (as defined in the Carnrick Agreement); and

      (c)   the Loan (as defined in the Loan Agreement)

      (together the "OUTSTANDING AMOUNTS")  -

Amarin acquires Further Equity Financing, Amarin shall within 5 (five) business
days of its receipt of Net Proceeds of such Further Equity Financing, pay EP Inc
and/or EPIL, as the case may be, from such Net Proceeds an amount equal to the
lesser of (i) one half of the Net Proceeds of such Further Equity Financing and
(ii) the balance of the Outstanding Amounts, in each case in partial or total
discharge of the Outstanding Amounts.

6.2.  Order of Application:

The Net Proceeds paid pursuant to Clause 6.1 shall be applied as between the
components of the Outstanding Amounts in such manner as Elan may direct. In the
absence of a direction by Elan, Amarin shall apply such sums in the order set
out in Clause 6.1.

6.3.  Effect of Payments:

      6.3.1   Sums paid pursuant to Clause 6.1 in partial discharge of the Total
              Divestiture Amount shall be credited in the manner provided in the
              Permax Agreement, that is to say against the latest payments in
              time due under Section 3.01(c) thereof first.

      6.3.2   Sums paid pursuant to Clause 6.1 in partial discharge of the Loan
              shall be treated as prepayments under the Loan Agreement, that is
              to say against the earliest payments in time due first. Solely for
              this purpose, EPIL waives the minimum prepayment amount.

6.4.  No Conflict With Permax Agreement:

In the event of any conflict between this Agreement and the Permax Agreement,
the provisions of this Agreement shall prevail.

7.    INVESTOR RELATIONS PROGRAM

Forthwith after the date of this Agreement, Amarin shall proactively initiate
and thereafter diligently pursue an investor relations programme to endeavour to
raise the profile of its ADRs.

8.    REPRESENTATIONS AND WARRANTIES

8.1.  Amarin represents and warrants to Elan that:

      8.1.1 it has the right, power, capacity and authority and has taken all
            action necessary to authorise it to execute and deliver and to
            exercise its rights and

                                     Page 6
<PAGE>
            perform its obligations under this Agreement, the Amendments, the
            subscription agreements and registration rights agreements
            contemplated by the PPM and any ancillary documents pertaining to
            the Refinancing (together "TRANSACTION DOCUMENTS"), and its
            obligations under the Transaction Documents are valid, legally
            binding and enforceable according to their terms, including
            obtaining all necessary approvals and consents from its shareholders
            and any third parties;

      8.1.2 the PPM together with the Transaction Documents sets out the
            entirety of the Refinancing; there are no other agreements,
            representations or understandings (written or oral) to which it is a
            party, or of which it is aware, pertaining to the Refinancing or
            conditional upon the Refinancing, other than a Share Purchase
            Agreement between EIS and certain investors in the Refinancing; the
            Refinancing is not conditional upon any act of Amarin, Elan, a party
            thereto, or any third party (other than the execution of this
            Agreement and/or the Amendments), or upon or any other contingency
            including the passage of time;

      8.1.3 there are no agreements between Amarin and any third party that
            conflict with the Transaction Documents;

      8.1.4 other than registration with the U.S. Securities and Exchange
            Commission as contemplated by the Registration Rights Agreement
            entered into in connection with the Refinancing and the Agreement
            listed as item (4) in Part B of Schedule 1, it does not require any
            further consents or approvals to consummate the transaction
            contemplated by the Transaction Documents including:

            8.1.4.1 approval of its shareholders; or

            8.1.4.2 approval of NASDAQ.

      8.1.5 as of the date hereof, neither Amarin nor any of its Affiliates has
            any indebtedness, secured or unsecured, outstanding to any third
            party other than Permitted Indebtedness (as defined in the Loan
            Agreement);

      8.1.6 the Panel of Takeovers and Mergers in London has confirmed to Amarin
            that the transaction constituted by the Transaction Documents is
            approved (including without any necessity for Elan to make any
            mandatory bid for the whole or any portion of Amarin's shares).

8.2.  Elan represents and warrants to Amarin that:

      8.2.1 it has the right, power, capacity and authority and has taken all
            action necessary to authorise it to execute and deliver and to
            exercise its rights and perform its obligations under this Agreement
            and the Amendments (together "ELAN TRANSACTION DOCUMENTS"), and its
            obligations under the Elan Transaction Documents are valid, legally
            binding and enforceable according to their terms, including
            obtaining all necessary approvals and consents from its shareholders
            and any third parties;

      8.2.2 there are no agreements between Elan and any third party that
            conflict with the Elan Transaction Documents;

                                     Page 7
<PAGE>
      8.2.3 it does not require any further consents or approvals to consummate
            the transaction contemplated by the Elan Transaction Documents
            including:

            8.2.3.1 approval of its shareholders; or

            8.2.3.2 approval of the New York Stock Exchange

9.    MISCELLANEOUS

9.1.  Confidentiality:

Except as provided in or anticipated by this Agreement, each party shall at all
times during the continuance of this Agreement use its respective best
endeavours to keep the contents of this Agreement and the Amendments
confidential and accordingly shall not disclose details of the contents of this
Agreement or the Amendments to any other person other than on a confidential
basis, it being acknowledged that Amarin may disclose the existence and terms of
this Agreement and the Transaction Documents to the investors in connection with
the Refinancing.

9.2.  Announcements:

Subject to Clause 9.3, no announcement or public statement concerning the
existence, subject matter or any term of this Agreement shall be made by or on
behalf of any party hereto without the prior written approval of the other party
(Elan Corp in the case of Elan).

The terms of any such announcement shall be agreed in good faith by the parties.

9.3.  Required Disclosures:

A party (the "DISCLOSING PARTY") will be entitled to make an announcement or
public statement concerning the existence, subject matter or any term of this
Agreement, or to disclose Confidential Information that the Disclosing Party is
required to make or disclose pursuant to:

      9.3.1 a valid order of a court or Governmental Authority; or

      9.3.2 any other requirement of law, regulation or any securities market or
            stock exchange;

provided that if the Disclosing Party becomes legally required to make such
announcement, public statement or disclosure hereunder, the Disclosing Party
shall give the other party or parties hereto prompt notice of such fact to
enable the other party or parties hereto to seek a protective order or other
appropriate remedy concerning any such announcement, public statement or
disclosure.

The Disclosing Party shall fully co-operate with the other party or parties
hereto in connection with that other party's or parties' efforts to obtain any
such order or other remedy.

If any such order or other remedy does not fully preclude announcement, public
statement or disclosure, the Disclosing Party shall make such announcement,
public statement or disclosure only to the extent that the same is legally
required.

9.4.  Assignment:

      9.4.1 Elan may assign this Agreement to any lawful assignee of the
            Existing Agreements as amended by the Amendments.

      9.4.2 Amarin shall not assign this Agreement without the prior written
            consent of Elan.

                                     Page 8
<PAGE>
9.5.  Parties bound:

This Agreement shall be binding upon and enure for the benefit of parties
hereto, their successors and permitted assigns.

9.6.  Severability:

If any provision in this Agreement is deemed to be, or becomes invalid, illegal,
void or unenforceable under applicable laws:-

      9.6.1 such provision will be deemed amended to conform to applicable laws
            so as to be valid and enforceable; or

      9.6.2 if it cannot be so amended without materially altering the intention
            of the parties, it will be deleted the validity, legality and
            enforceability of the remaining provisions of this Agreement shall
            not be impaired or affected in any way.

9.7.  Relationship of the parties:

      9.7.1 Nothing contained in this Agreement is intended or is to be
            construed to constitute any of the parties hereto as partners or
            members of a joint venture or any party as an employee of another
            party.

      9.7.2 No party hereto shall have any express or implied right or authority
            to assume or create any obligations on behalf of or in the name of
            any other party or to bind another party to any contract, agreement
            or undertaking with any third party.

9.8.  Amendments:

No amendment, modification or addition hereto shall be effective or binding on
any party hereto unless set forth in writing and executed by a duly authorised
representative of all parties hereto.

9.9.  Waiver:

No waiver of any right under this Agreement shall be deemed effective unless
contained in a written document signed by the party charged with such waiver,
and no waiver of any breach or failure to perform shall be deemed to be a waiver
of any future breach or failure to perform or of any other right arising under
this Agreement.

9.10. Entire agreement:

      9.10.1 Each of the parties hereto hereby acknowledges that in entering
             into this Agreement it has not relied on any representation or
             warranty except as expressly set forth herein or in any document
             referred to herein.

      9.10.2 This Agreement and the Amendments together set forth all of the
             agreements and understandings between the parties with respect to
             the subject matter hereof, and supersedes and terminates all prior
             agreements and understandings between the parties with respect to
             the subject matter hereof. There are no agreements or
             understandings with respect to the subject matter hereof, either
             oral or written, between the Parties other than as set forth in
             this Agreement.

      9.10.3 Nothing in this Clause 9.10 shall exclude any liability which any
             party would otherwise have to the other party or any right which
             either of them may have

                                     Page 9
<PAGE>
            to rescind this Agreement in respect of any statements made
            fraudulently by the other prior to the execution of this Agreement
            or any rights which either of them may have in respect of fraudulent
            concealment by the other.

9.11. Governing law and jurisdiction:

      9.11.1 This Agreement shall be governed by and construed in accordance
             with English law.

      9.11.2 For the purposes of this Agreement the parties submit to the
             jurisdiction of the English courts.

9.12. Notice:

      9.12.1 Any notice to be given under this Agreement shall be sent in
             writing in English by registered or recorded delivery post,
             reputable overnight courier or fax to:

             Elan at

             Elan International Services Ltd.
             102 St. James Court
             Flatts,
             Smiths FL04
             Bermuda

             Attention:  Secretary
             Fax:        +1 441 292 2224

             Amarin at

             7 Curzon Street
             London
             W1J 5HG
             England

             Attention:  General Counsel & Company Secretary
             Fax:        +44 20 7499 9004

             or to such other address(es) and fax numbers as may from time to
             time be notified by either party to the other hereunder.

      9.12.2 Any notice sent by mail shall be deemed to have been delivered
             within 7 working days after despatch or delivery to the relevant
             courier and any notice sent by fax shall be deemed to have been
             delivered upon confirmation of receipt. Notice of change of address
             shall be effective upon receipt.

9.13. Further assurances:

At the request of any of the parties, the other party or parties shall (and
shall use reasonable efforts to procure that any other necessary third parties
shall) execute all such documents, and so all such acts and things as may
reasonably be required subsequent to the signing of this Agreement for assuring
to or vesting in the requesting party the full benefit of the terms hereof.

                                     Page 10
<PAGE>
Additionally, to the extent that the consent of RP Scherer Corporation may be
needed to Amendment number (3) in Part B of Schedule 1, and/or to effect the
transaction thereby contemplated, the parties shall reasonably cooperate with
each other with a view to securing such consent and further (at Elan's option)
Amarin shall use its best efforts to secure such consent.

9.14. Counterparts:

This Agreement may be executed in any number of counterparts, each of which when
so executed shall be deemed to be an original and all of which when taken
together shall constitute this Agreement.

9.15. Contracts (Rights of Third Parties) Act 1999:

A person who is not a party to this Agreement has no right under the Contracts
(Rights of Third Parties) Act 1999 to enforce any term of this Agreement, but
this does not affect any right or remedy of a third party which exists or is
available apart from that Act.

IN WITNESS whereof the parties have executed this Agreement on the date first
above written.

                                    Page 11
<PAGE>
                  SCHEDULE 1 EXISTING AGREEMENTS AND AMENDMENTS

                          PART A - EXISTING AGREEMENTS

(1)   Loan Agreement dated 28 September 2001 between Amarin and EPIL, as varied
      by (i) a Deed of Variation dated 19 July 2002 and (ii) a Deed of Variation
      No. 2 dated 23 December 2002.

(2)   Amended and Restated Distribution, Marketing and Option Agreement dated 28
      September 2001 (which agreement concerned the product Permax), by and
      between EP Inc and Amarin.

(3)   Amended and Restated Asset Purchase Agreement dated as of 29 September
      1999 (which agreement concerned certain products known as the "Carnrick
      products") by and between EP Inc and Amarin, as varied.

(4)   Option Agreement dated 28 June 2001 (which agreement concerned the product
      Zelapar), between EPIL and Amarin.

(5)   Registration Rights Agreement dated as of 21 October 1998 between
      Amarin (sub. former name Ethical Holdings plc) and Monksland.

                               PART B - AMENDMENTS

(1)   Deed of Variation No. 3 relating to the Loan Agreement dated 28
      September 2001 as amended by Deed of Variation dated 19 July 2002,
      between Amarin and EPIL.

(2)   Deed of Variation relating to the Amended and Restated Distribution,
      Marketing and Option Agreement dated 28 September 2001 (which agreement
      concerned the product Permax), between EP Inc and Amarin.

(3)   Deed of Variation relating to the Option Agreement dated 28 June 2001
      (which agreement concerned the product Zelapar), between EPIL and Amarin.

(4)   Agreement between Amarin, Monksland and EIS relating to the conversion of
      preference shares and certain restrictions on dealing.

(5)   Amendment No. 1 to Registration Rights Agreement And Waiver relating
      to the Registration Rights Agreement dated as of 21 October 1998,
      between Amarin, Monksland and EIS.

Each of which is attached hereto and is in final and definitive form.

                                     Page 12
<PAGE>
                             SCHEDULE 2 REFINANCING

The Refinancing is set out in detail in the PPM and involves Amarin raising at
least US$17.5 million and a maximum of US$30 million through the sale to
investors of ordinary shares of Pound Sterling 1 each. These securities will be
priced at a per share price equal to 90% of the average closing prices of
Amarin's ADSs on the Nasdaq National Market over the five trading days ending on
the trading day immediately before the closing date of the Refinancing. The
minimum investment by an investor is US$500,000. Amarin may, however, agree to
accept less than the minimum investment.

                                     Page 13
<PAGE>
SIGNED                                    SIGNED

/s/ William Daniel                        /s/ William Daniel
For and on behalf of                      For and on behalf of
ELAN CORPORATION, PLC.                    ELAN PHARMA INTERNATIONAL LIMITED

SIGNED                                    SIGNED

/s/ Kevin Insley                          /s/ Michael Pagnotta
For and on behalf of                      For and on behalf of
ELAN INTERNATIONAL SERVICES, LTD.         ELAN PHARMACEUTICALS, INC.

SIGNED                                    SIGNED

/s/ Pieter Bosse and Klass Van Blanken    /s/ Richard Stewart
For and on behalf of                      For and on behalf of
MONKSLAND HOLDINGS BV                     AMARIN CORPORATION PLC.

                                     Page 14<PAGE>

                                                                    Exhibit 4.21

                                   DATED 2003

                    ________________________________________

                                WARRANT AGREEMENT

                                     between

                             AMARIN CORPORATION PLC

                                       and

                                       [o]

                    ________________________________________

<PAGE>

THE WARRANT DESCRIBED HEREIN HAS NOT BEEN REGISTERED UNDER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR REGISTERED OR
QUALIFIED UNDER ANY APPLICABLE STATE SECURITIES LAWS. SUCH WARRANT MAY NOT BE
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND REGISTERED OR
QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS OR (B) AN EXEMPTION FROM SUCH
REGISTRATION OR QUALIFICATION REQUIREMENTS IS AVAILABLE. AS A CONDITION TO
PERMITTING ANY TRANSFER OF SUCH WARRANT, THE COMPANY MAY REQUIRE THAT IT BE
FURNISHED WITH AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY TO THE EFFECT
THAT NO REGISTRATION OR QUALIFICATION IS LEGALLY REQUIRED FOR SUCH TRANSFER.

                                      -2-

<PAGE>

THIS WARRANT AGREEMENT is made on [o] 2003

PARTIES:

(1)  Amarin Corporation plc, a public company organized under the laws of
     England and Wales, having its principal place of business at 7 Curzon
     Street, London W1J 5HG, England (the "Company"); and

(2)  [o] (the "Holder").

WHEREAS:

(A)  Securities Research Associates, Inc. ("SRA") assisted the Company in the
     Company's private placement of the Company's ordinary shares, par value
     Pound Sterling 1 per share ("Ordinary Shares"), which was completed on 27
     January 2003 at a price per Ordinary Share of US$ 3.4785.

(B)  In partial consideration of such services, SRA has requested that the
     Company, and the Company has agreed to, subject to the terms and conditions
     hereof, grant the Holder the right to subscribe for [o] Ordinary Shares at
     a fixed price per share of US$ 3.4785.

(C)  This Warrant Agreement is intended to take effect as a deed.

IT IS AGREED as follows:

1.   PURCHASE RIGHTS

(a)  The Holder shall, upon the terms and subject to the conditions hereinafter
     set forth, at any time, and from time to time, on or after January 27, 2004
     and at or prior to the Expiration Time (as defined below), but not
     thereafter, have the right (the "Warrant") to subscribe for up to [o] fully
     paid new Ordinary Shares at a subscription price equal to US$ 3.4785 per
     share (the "Exercise Price"). Such number of Ordinary Shares, type of
     security and Exercise Price are subject to adjustment as provided herein,
     and all references to "Ordinary Shares" and "Exercise Price" herein shall
     be deemed to include any such adjustment or series of adjustments.

(b)  The Exercise Price shall not be less than the nominal amount per share for
     the time being of the Ordinary Shares and, in the event that the Pounds
     Sterling equivalent of the Exercise Price at the close of business on the
     date upon which the Company receives payment for value of the aggregate
     Exercise Price in respect of Ordinary Shares subscribed pursuant to an
     exercise of the Warrant is less than the nominal amount of an Ordinary
     Share, the Exercise Price in respect of each Ordinary Share so subscribed
     shall be increased to an amount in Pounds Sterling equal to such nominal
     amount or its equivalent in any other currency.

                                      -3-

<PAGE>

(c)  The Company undertakes that upon exercise of the Warrant by the Holder in
     accordance with the terms and conditions set forth below it shall issue and
     deliver to the Holder in accordance with the terms and conditions set forth
     herein free of charge a share certificate or certificates in respect of the
     Ordinary Shares issued pursuant to such exercise of the Warrant.

2.   TERMINATION AND EXPIRATION

     If not earlier exercised, the Warrant shall expire on the earliest to occur
     of (i) 5:00 p.m. (London, England time) January 26, 2008, and (ii) the
     consummation of a merger or consolidation with or into another person by
     the Company or the transfer (whether in one transaction or in a series of
     transactions) of all or substantially all of the Company's assets (whenever
     acquired) (such earliest date, the "Expiration Time").

3.   EXERCISE OF WARRANT

     The Warrant may be exercised in whole or in part on any one or more
     occasions. In order to exercise its Warrant in whole or in part, the Holder
     must, not earlier than January 28, 2004 and not later than the Expiration
     Time, deliver to the Company a completed and duly executed Notice of
     Exercise in the form attached at Schedule 1 hereto, at the Company's
     address described in Section 16, accompanied by payment in full of the
     aggregate Exercise Price for the Ordinary Shares thereby subscribed (by
     cash or by check or bank draft payable to the order of the Company in an
     amount equal to such aggregate Exercise Price); whereupon the Holder shall
     be entitled to be issued the number of Ordinary Shares so subscribed and
     receive from the Company a share certificate in proper form representing
     such Ordinary Shares, and this Warrant Agreement shall be deemed amended in
     that the Warrant shall thereupon represent the right to subscribe that
     number of Ordinary Shares equal to the difference, if any, between the
     number of Ordinary Shares subject thereto immediately prior to such
     exercise and the number of Ordinary Shares as to which the Warrant is so
     exercised.

4.   ISSUANCE OF SHARES

     Ordinary Shares subscribed upon an exercise of the Warrant shall be issued
     to the Holder and a certificate in respect thereof shall be dispatched to
     the Holder promptly after the date on which the Warrant shall have been
     exercised in accordance with the terms hereof. No fraction of an Ordinary
     Share will be issued on the exercise of the Warrant and no refund will be
     made to the Holder in respect of any monies paid by the Holder which
     represents such a fraction (if any).

5.   CHARGES, TAXES AND EXPENSES

     Issuance of certificates in respect of Ordinary Shares upon the exercise of
     the Warrant shall be made without charge to the Holder for any issue or
     transfer tax, stamp duty or other incidental expense in respect of the
     issuance of such

                                      -4-

<PAGE>

     certificate, all of which taxes and expenses shall be paid by the Company,
     and such certificates shall be issued in the name of the Holder.

6.   RIGHTS AS SHAREHOLDER

     The Holder shall not be entitled to vote upon any matter submitted to
     shareholders of the Company at any meeting thereof, or to receive notice of
     such meetings, or be deemed the holder of Ordinary Shares until the Warrant
     shall have been exercised in whole or in part and the Ordinary Shares
     subscribed for upon such exercise shall have been issued to the Holder, as
     provided herein. Ordinary Shares issued pursuant to the exercise of the
     Warrant will not rank for any dividends or other distributions declared,
     paid or made by reference to a record date prior to the date upon which
     they are issued but, subject thereto, will rank in full for all dividends
     and other distributions declared, made or paid on the Ordinary Shares in
     respect of the then current financial year and pari passu in all other
     respects with the Ordinary Shares in issue on such issue date.

7.   TRANSFER RESTRICTIONS

(a)  The exercise of the Warrant by the Holder will be subject to such
     requirements, conditions, restrictions, limitations or prohibitions as the
     Company may at any time impose, in its sole discretion, for the purpose of
     complying with (or not requiring to comply with) the securities laws of the
     United States (including, without limitation, the United States Securities
     Act of 1933, as amended, and the rules and regulations of the Securities
     and Exchange Commission or any other federal agency at the time
     administering the Securities Act (the "Commission") promulgated thereunder
     (the "Securities Act")) or any other applicable securities laws.

(b)  The Holder understands that (i) the Warrant and the Ordinary Shares which
     may be issued upon exercise thereof have not been registered under the
     Securities Act or the securities laws of any state or other jurisdiction in
     reliance upon exemptions, including an exemption pursuant to Rule 506 under
     the Securities Act, from such registration requirements for non-public
     offerings; (ii) the Warrant and the Ordinary Shares which may be issued
     upon exercise thereof may not be re-offered, resold, pledged or otherwise
     transferred unless they have been first registered under the Securities Act
     and all applicable state securities laws, or unless exemptions from such
     registration provisions are available with respect to said resale or
     transfer; and (iii) except as set forth in Section 8 hereof, the Company is
     under no obligation to register the Warrant or the Ordinary Shares which
     may be issued upon exercise thereof under the Securities Act or any state
     securities laws, or to take any action to make any exemption from any such
     registration provisions available.

(c)  The Holder understands and agrees that each certificate or other document
     evidencing the Warrant or any of the Ordinary Shares which may be issued
     upon exercise of the Warrant shall be endorsed with a legend in
     substantially the form

                                      -5-

<PAGE>

     set forth below as well as any other legends required by applicable law,
     and the Holder covenants that the Holder shall not transfer the securities
     represented by any such certificate without complying with the restrictions
     on transfer described in the legends endorsed on such certificate or other
     document:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
     ACT"), OR REGISTERED OR QUALIFIED UNDER ANY APPLICABLE STATE SECURITIES
     LAWS. THESE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
     TRANSFERRED UNLESS (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
     UNDER THE SECURITIES ACT AND REGISTERED OR QUALIFIED UNDER APPLICABLE STATE
     SECURITIES LAWS OR (B) AN EXEMPTION FROM SUCH REGISTRATION OR QUALIFICATION
     REQUIREMENTS IS AVAILABLE. AS A CONDITION TO PERMITTING ANY TRANSFER OF
     THESE SECURITIES, THE COMPANY MAY REQUIRE THAT IT BE FURNISHED WITH AN
     OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY TO THE EFFECT THAT NO
     REGISTRATION OR QUALIFICATION IS LEGALLY REQUIRED FOR SUCH TRANSFER.

     NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE FOREGOING, THE SECURITIES
     MAY NOT BE DEPOSITED INTO ANY DEPOSITARY RECEIPT FACILITY IN RESPECT OF THE
     SECURITIES ESTABLISHED UNLESS AND UNTIL SUCH TIME AS A REGISTRATION
     STATEMENT IS IN EFFECT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT OR
     UNLESS THE OFFER AND SALE OF SUCH SECURITIES IS EXEMPT FROM REGISTRATION
     UNDER THE PROVISIONS OF THE SECURITIES ACT.

(d)  The Holder may not sell, assign, transfer, pledge or otherwise encumber
     either voluntarily or by operation of law any of its rights or obligations
     (including the Warrant) under this Warrant Agreement without the prior
     written consent of the Company.

8.   REGISTRATION RIGHTS

(a)  As used in this Section 8, the following terms shall have the following
     respective meanings:

     (i)   "Blackout Period" shall mean, with respect to a registration
           statement, a period or periods not in excess of an aggregate 90
           calendar days in any calendar year during which the Company, in the
           good faith judgment of its Board of Directors, determines (because of
           the existence of, or in anticipation of, any acquisition, financing
           activity, or other transaction involving the Company, or the
           unavailability for reasons beyond the Company's control of any
           required financial statements, disclosure of

                                      -6-

<PAGE>

           information which is in its best interest not to publicly disclose,
           or any other event or condition of similar significance to the
           Company) that the registration and distribution of the Registrable
           Securities to be covered by such registration statement, if any,
           would be seriously detrimental to the Company and its shareholders.

     (ii)  "EIS Registration Rights Agreement" shall mean that certain
           Registration Rights Agreement, dated as of October 21, 1998, by and
           among the Company, f/k/a Ethical Holdings plc, and Monksland Holdings
           B.V. ("Monksland"), as amended by Amendment No. 1 to Registration
           Rights Agreement and Waiver, dated January 27, 2003, by and among the
           Company, Monksland and Elan International Services, Ltd. ("EIS").

     (iii) "Exchange Act" shall mean the Securities Exchange Act of 1934, as
           amended, and the rules and regulations of the Commission promulgated
           thereunder.

     (iv)  "Investors' Registration Rights Agreement" shall mean that certain
           Registration Rights Agreement, dated as of January 27, 2003, by and
           among the Company and the parties set forth on the signature pages
           thereto.

     (v)   The terms "register", "registered" and "registration" refers to a
           registration effected by preparing and filing a registration
           statement in compliance with the Securities Act, and the declaration
           or ordering of the effectiveness of such registration statement.

     (vi)  "Registrable Securities" shall mean Ordinary Shares issued to the
           Holder pursuant to the Holder's exercise of its Warrant in accordance
           with the terms and provisions of this Warrant Agreement, excluding
           (A) any such Ordinary Shares that have been publicly sold or may be
           sold immediately without registration under the Securities Act either
           pursuant to Rule 144 of the Securities Act or otherwise; (B) any such
           Ordinary Shares sold by a person in a transaction pursuant to a
           registration statement filed under the Securities Act or (C) any such
           Ordinary Shares that are at the time subject to an effective
           registration statement under the Securities Act.

(b)  Subject to the terms and conditions hereof, as promptly as reasonably
     practicable after the date hereof, but in any event not later than April
     24, 2003, the Company shall use its reasonable efforts to file a shelf
     registration statement on Form F-1 or, if the Company is eligible to use
     such form, Form F-3 relating to the resale by the Holder of the Registrable
     Securities from time to time in accordance with the methods of distribution
     set forth in such registration statement and Rule 415 under the Securities
     Act; provided, however, that the Company shall not be obligated to effect
     any such registration pursuant to this Section 8, or to keep such
     registration effective pursuant to this Section 8, during any Blackout
     Period or if the means of distribution involves an underwritten offering;
     and provided further, that if the

                                      -7-

<PAGE>

     Company does not meet the eligibility requirements to use such Form F-1 or
     F-3, it shall instead use its reasonable efforts to file a shelf
     registration statement on Form S-1 or S-3, as the case may be. The Holder
     hereby acknowledges that any registration statement filed pursuant to this
     Section 8 will include Ordinary Shares held by other shareholders of the
     Company.

(c)  In the case of the registration effected by the Company pursuant to Section
     8 hereof, the Company will keep the Holder reasonably advised in writing as
     to the initiation of each registration and as to the completion thereof.
     Subject to the terms and conditions hereof, at its expense with respect to
     any registration statement filed pursuant to Section 8, the Company will
     use its reasonable efforts to:

     (i)   prepare and file with the Commission with respect to such Registrable
           Securities a shelf registration statement on Form F-1 (or S-1, as the
           case may be) or, if the Company is eligible to use such form, Form
           F-3 (or S-3, as the case may be), and use its reasonable efforts to
           cause such registration statement to become and remain effective
           until the earliest of (A) two years from the date the registration
           statement is declared effective by the Commission and (B) the date
           on which (1) all Ordinary Shares of EIS and Monksland included in
           such registration statement have either been sold or registered by
           means of a registration statement requested by EIS and Monksland
           pursuant to the EIS Registration Rights Agreement and (2) all other
           Ordinary Shares included in such registration statement (including
           the Registrable Securities) have either been sold or are eligible to
           be immediately, freely resold without restriction under Rule 144
           under the Securities Act (the "Effectiveness Period");

     (ii)  prepare and file with the Commission such amendments and supplements
           to such registration statement and the prospectus used in connection
           therewith as may be necessary to keep such registration statement
           effective during the Effectiveness Period;

     (iii) furnish, without charge, to the Holder of Registrable Securities
           covered by such registration statement one signed copy of such
           registration statement (excluding any exhibits thereto other than
           applicable underwriting documents), each amendment and supplement
           thereto (including one conformed copy to the Holder, including all
           exhibits thereto), and such number of copies of the prospectus
           included in such registration statement (including each preliminary
           prospectus and any other prospectus filed under Rule 424 under the
           Securities Act) as the Holder may reasonably request, in conformity
           with the requirements of the Securities Act;

     (iv)  register or qualify such Registrable Securities under such other
           applicable securities or blue sky laws of such jurisdictions as the
           Holder of Registrable Securities covered by such registration
           statement reasonably requests as may be necessary for the
           marketability of the Registrable

                                      -8-

<PAGE>

           Securities (such request to be made not more than ten days after the
           applicable registration statement is filed with the Commission) and
           do any and all other acts and things which may be reasonably
           necessary or advisable to enable the Holder to consummate the
           disposition in such jurisdictions of the Registrable Securities
           owned by the Holder; provided that the Company shall not be required
           to (A) qualify generally to do business in any particular
           jurisdiction in which the Company would be required to qualify to do
           business as a foreign corporation or as a dealer in securities under
           the securities or blue sky laws of such jurisdiction or to execute a
           general consent to service of process in effecting such
           registration, qualification or compliance, in each case where it has
           not already done so, or (B) subject itself to taxation in any such
           jurisdiction, or (C) consent to general service of process in any
           such jurisdiction;

     (v)   promptly notify the Holder of such Registrable Securities at any
           time when a prospectus relating thereto is required to be delivered
           under the Securities Act of the happening of any event which comes
           to the Company's attention if as a result of such event the
           prospectus included in such registration statement contains an
           untrue statement of a material fact or omits to state any material
           fact required to be stated therein or necessary to make the
           statements therein not misleading and the Company shall promptly
           prepare and furnish to the Holder a supplement or amendment to such
           prospectus (or prepare and file appropriate reports under the
           Exchange Act) so that, as thereafter delivered to the purchasers of
           such Registrable Securities, such prospectus shall not contain an
           untrue statement of a material fact or omit to state any material
           fact required to be stated therein or necessary to make the
           statements therein not misleading, unless suspension of the use of
           such prospectus otherwise is authorized herein or in the event of a
           Blackout Period, in which case no supplement or amendment need be
           furnished (or Exchange Act filing made) until the termination of
           such suspension or Blackout Period; and

     (vi)  comply, and continue to comply during the period that such
           registration statement is effective under the Securities Act, in all
           material respects with the Securities Act and the Exchange Act and
           with all applicable rules and regulations of the Commission with
           respect to the disposition of all securities covered by such
           registration statement, and make available to its security holders,
           as soon as reasonably practicable, an earnings statement covering
           the period of at least twelve months, but not more than eighteen
           months, beginning with the first full calendar month after the
           effective date of such registration statement, which earnings
           statement shall satisfy the provisions of Section 11(a) of the
           Securities Act.

     The Holder agrees that, upon receipt of any notice from the Company of the
     happening of any event of the kind described in Section 8(c)(v) hereof or
     of the commencement of a Blackout Period, the Holder shall discontinue
     disposition of Registrable Securities pursuant to the registration
     statement covering such

                                      -9-

<PAGE>

     Registrable Securities until the Holder's receipt of the copies of the
     supplemented or amended prospectus contemplated by Section 8(c)(v) hereof
     or notice of the end of the Blackout Period, and, if so directed by the
     Company, the Holder shall deliver to the Company (at the Company's
     expense) all copies (including, without limitation, any and all drafts),
     other than permanent file copies, then in the Holder's possession, of the
     prospectus covering such Registrable Securities current at the time of
     receipt of such notice.

(d)  The Company shall pay all expenses in connection with any registration,
     including, without limitation, all registration, filing, stock exchange and
     NASD fees, printing expenses, all fees and expenses of complying with
     securities or blue sky laws, the fees and disbursements of counsel for the
     Company and of its independent accountants. In addition, should the Holder
     determine to retain such counsel, reasonably acceptable to the Company, as
     may be selected by the holders of a majority of the Registrable Securities
     (as such term is defined in the Investors' Registration Rights Agreement)
     included in such registration statement pursuant to Section 4 of the
     Investors' Registration Rights Agreement to represent the Holder in
     connection with the registration of the Registrable Securities hereunder
     (the "Holders Counsel"), then the Company shall pay the reasonable fees of
     the Holders Counsel; provided, however, that the fees and disbursements of
     Holders' Counsel payable by the Company with respect to the Holders
     Counsel's representation of the Holder and the all other selling
     shareholders under the registration statement shall not exceed in the
     aggregate $10,000. Except as provided in this Section 8, the Company shall
     not be responsible for the expenses of any attorney or other advisor
     employed by the Holder of Registrable Securities.

(e)  The Holder of Registrable Securities included in any registration shall
     furnish to the Company in a timely manner such information regarding the
     Holder and the distribution proposed by the Holder as the Company may from
     time to time reasonably request in writing. The Holder shall not be
     entitled to be named as a selling security holder in a registration
     statement or have its Registrable Securities included therein, and the
     Holder shall not be entitled to use the prospectus forming a part thereof
     for resales of Registrable Securities at any time, unless the Holder has
     furnished such information within a reasonable time after receiving such a
     request.

(f)  Indemnification.

     (i)   In the event of the offer and sale of Registrable Securities held by
           the Holder under the Securities Act, the Company shall, and hereby
           does, indemnify and hold harmless, to the fullest extent permitted
           by law, the Holder, its directors, officers, partners and each
           person, if any, who controls or is under common control with the
           Holder within the meaning of Section 15 of the Securities Act,
           against any losses, claims, damages or liabilities, joint or
           several, and expenses to which the Holder or any such director,
           officer, partner or controlling person may become subject under the
           Securities Act or otherwise, insofar as such losses, claims,
           damages,

                                      -10-

<PAGE>

           liabilities or expenses (or actions or proceedings, whether
           commenced or threatened, in respect thereof) arise out of or are
           based upon any untrue statement or alleged untrue statement of any
           material fact contained in any registration statement under which
           such shares were registered under the Securities Act, any
           preliminary prospectus, final prospectus or summary prospectus
           contained therein, or any amendment or supplement thereto, or any
           omission or alleged omission to state therein a material fact
           required to be stated therein or necessary to make the statements
           therein in light of the circumstances in which they were made not
           misleading, and the Company shall reimburse the Holder, and each
           such director, officer, partner and controlling person for any legal
           or any other expenses reasonably incurred by them in connection with
           investigating, defending or settling any such loss, claim, damage,
           liability, action or proceeding; provided that (A) the Company shall
           not be liable in any such case to the extent that any such loss,
           claim, damage, liability (or action or proceeding in respect
           thereof) or expense arises out of or is based upon an untrue
           statement or alleged untrue statement in or omission or alleged
           omission from such registration statement, any such preliminary
           prospectus, final prospectus, summary prospectus, amendment or
           supplement in reliance upon and in conformity with written
           information furnished to the Company or through an instrument duly
           executed by or on behalf of the Holder specifically stating that it
           is for use in the preparation thereof, and (B) the foregoing
           indemnity with respect to any untrue statement or alleged untrue
           statement in or omission or alleged omission from such registration
           statement, any such preliminary prospectus, final prospectus,
           summary prospectus, amendment or supplement, shall not inure to the
           benefit of the Holder (or any person controlling the Holder) from
           whom the person asserting any such losses, claims, damages,
           liabilities or expenses purchased the securities concerned, to the
           extent that a prospectus (as then amended or supplemented) relating
           to such securities was required by law to be delivered to such
           person under the Securities Act and the Holder failed to send or
           give to such person a copy of the prospectus (as then amended or
           supplemented) if the Company had previously furnished copies thereof
           to the Holder and if the prospectus (as then amended or
           supplemented) would have cured the defect giving rise to such loss,
           claim, damage, liability or expense. Such indemnity shall remain in
           full force and effect regardless of any investigation made by or on
           behalf of the Holder, or any such director, officer, partner or
           controlling person and shall survive the transfer of such shares by
           the Holder.

     (ii)  The Holder shall, and hereby does, indemnify and hold the Company,
           its directors and officers and each other person, if any, who
           controls the Company within the meaning of Section 15 of the
           Securities Act, against any losses, claims, damages or liabilities,
           joint or several, to which the Company or any such director or
           officer or controlling person may become subject under the
           Securities Act or otherwise, insofar as such

                                      -11-

<PAGE>

           losses, claims, damages or liabilities (or actions or proceedings,
           whether commenced or threatened, in respect thereof) arise out of or
           are based upon any untrue statement or alleged untrue statement in
           or omission or alleged omission from such registration statement,
           any preliminary prospectus, final prospectus or summary prospectus
           contained therein, or any amendment or supplement thereto, if such
           statement or alleged statement or omission or alleged omission was
           made in reliance upon and in conformity with written information
           about the Holder as the Holder furnished to the Company, and the
           Holder shall reimburse the Company, and each such director, officer,
           partner and controlling person for any legal or any other expenses
           reasonably incurred by them in connection with investigating,
           defending or settling any such loss, claim, damage, liability,
           action or proceeding. Such indemnity shall remain in full force and
           effect, regardless of any investigation made by or on behalf of the
           Company or any such director, officer or controlling person and
           shall survive the transfer by the Holder of such shares.

     (iii) Promptly after receipt by an indemnified party of notice of the
           commencement of any action or proceeding involving a claim referred
           to in Section 8(f)(i) or (ii) hereof (including any governmental
           action), such indemnified party shall, if a claim in respect thereof
           is to be made against an indemnifying party, give written notice to
           the indemnifying party of the commencement of such action; provided
           that the failure of any indemnified party to give notice as provided
           herein shall not relieve the indemnifying party of its obligations
           under Section 8(f)(i) or (ii) hereof, except to the extent that the
           indemnifying party is actually prejudiced by such failure to give
           notice. In case any such action is brought against an indemnified
           party, unless in the reasonable judgment of counsel to such
           indemnified party a conflict of interest between such indemnified
           and indemnifying parties may exist or the indemnified party may have
           defenses not available to the indemnifying party in respect of such
           claim, the indemnifying party shall be entitled to participate in
           and to assume the defense thereof, with counsel reasonably
           satisfactory to such indemnified party and, after notice from the
           indemnifying party to such indemnified party of its election so to
           assume the defense thereof, the indemnifying party shall not be
           liable to such indemnified party for any legal or other expenses
           subsequently incurred by the latter in connection with the defense
           thereof, unless in such indemnified party's reasonable judgment a
           conflict of interest between such indemnified and indemnifying
           parties arises in respect of such claim after the assumption of the
           defenses thereof or the indemnifying party fails to defend such
           claim in a diligent manner, other than reasonable costs of
           investigation. Neither an indemnified nor an indemnifying party
           shall be liable for any settlement of any action or proceeding
           effected without its consent which shall not be unreasonably
           withheld. No indemnifying party shall, without the consent of the
           indemnified party, consent to entry of any judgment or enter into
           any settlement that does not include as an unconditional term
           thereof the

                                      -12-

<PAGE>

           giving by the claimant or plaintiff to such indemnified party of a
           release from all liability in respect of such claim or litigation.
           Notwithstanding anything to the contrary set forth herein, and
           without limiting any of the rights set forth above, in any event any
           party shall have the right to retain, at its own expense, counsel
           with respect to the defense of a claim.

     (iv)  In the event that an indemnifying party does or is not permitted to
           assume the defense of an action pursuant to Section 8(f)(iii) or in
           the case of the expense reimbursement obligation set forth in
           Section 8(f)(i) or (ii), the indemnification required by Sections
           8(f)(i) and (ii) hereof shall be made by periodic payments of the
           amount thereof during the course of the investigation or defense, as
           and when bills are received or expenses, losses, damages, or
           liabilities are incurred.

     (v)   If the indemnification provided for in this Section 8 is held by a
           court of competent jurisdiction to be unavailable to an indemnified
           party with respect to any loss, liability, claim, damage or expense
           referred to herein, the indemnifying party, in lieu of indemnifying
           such indemnified party hereunder, (A) shall contribute to the amount
           paid or payable by such indemnified party as a result of such loss,
           liability, claim, damage or expense as is appropriate to reflect the
           proportionate relative fault of the indemnifying party on the one
           hand and the indemnified party on the other (determined by reference
           to, among other things, whether the untrue or alleged untrue
           statement of a material fact or omission relates to information
           supplied by the indemnifying party or the indemnified party and the
           parties' relative intent, knowledge, access to information and
           opportunity to correct or prevent such untrue statement or
           omission), or (B) if the allocation provided by clause (A) above is
           not permitted by applicable law, the indemnifying party shall
           contribute to the amount paid or payable by such indemnified party
           as a result of such loss, liability, claim, damage or expense as is
           appropriate to reflect not only the proportionate relative fault of
           the indemnifying party and the indemnified party, but also the
           relative benefits received by the indemnifying party on the one hand
           and the indemnified party on the other, as well as any other
           relevant equitable considerations. No indemnified party guilty of
           fraudulent misrepresentation (within the meaning of Section 11(f) of
           the Securities Act) shall be entitled to contribution from any
           indemnifying party who was not guilty of such fraudulent
           misrepresentation.

     (vi)  Indemnification similar to that specified in the preceding
           subsections of this Section 8(f) (with appropriate modifications)
           shall be given by the Company and the Holder of Registrable
           Securities with respect to any required registration or other
           qualification of securities under any federal or state law or
           regulation or governmental authority other than the Securities Act.

                                      -13-

<PAGE>

9.   SATURDAYS, SUNDAYS AND HOLIDAYS

     If the last or appointed day for the taking of any action or the expiration
     of any right required or granted herein shall be a Saturday or a Sunday or
     shall be a bank holiday, then such action may be taken or such right may be
     exercised on the next succeeding business day.

10.  ADJUSTMENT TO NUMBER AND TYPE OF SECURITIES, EXERCISE PRICE

     The type and number of securities of the Company which may be issued upon
     exercise of the Warrant and the Exercise Price are subject to adjustment as
     set forth below:

(a)  The Exercise Price and the number and type of securities or other property
     which may be issued upon exercise of the Warrant shall be appropriately and
     proportionately adjusted to reflect any share dividend, combination of
     shares, reclassification, capitalization of profits or reserves,
     consolidation, redemption or other similar event affecting the number or
     character of Ordinary Shares outstanding, so that the number and type of
     securities or other property which may be issued upon exercise of the
     Warrant shall be equal to that which would have been issued with respect to
     the number of Ordinary Shares subject to such Warrant at the time of such
     event, had such Ordinary Shares then been outstanding.

(b)  In case of any adjustment in the Exercise Price or number and type of
     securities which may be issued upon exercise of the Warrant, the Company
     will promptly give written notice thereof to the Holder and this Warrant
     Agreement shall be deemed amended to reflect such adjustment.

11.  NOTICES OF RECORD DATE, ETC.

     In the event of:

(a)  any taking by the Company of a record of the holders of Ordinary Shares for
     the purpose of determining the holders who are entitled to receive any
     dividend or other distribution,

(b)  any capital reorganization of the Company, any reclassification or
     recapitalization of the share capital of the Company, or any transfer of
     all or substantially all the assets of the Company to, or consolidation or
     merger of, the Company with or into any person,

(c)  any compulsory or voluntary winding-up, or liquidation of the Company, or

(d)  a sale of substantially all of the outstanding share capital of the Company
     or the issuance of new shares representing the majority of the Company's
     right to vote,

                                      -14-

<PAGE>

     then and in each such event the Company will mail to the Holder a notice
     specifying the record date for voting or the date of closing, as
     applicable, of any event described in (a) through (d) above. Where
     practicable such notice shall be delivered to the Holder at least 10 days
     prior to the date of the relevant event.

12.  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

     The Company hereby represents, warrants and agrees that:

(a)  during the period the Warrant is outstanding, the Company will keep
     available for issue sufficient authorized but unissued share capital to
     provide for the issuance of Ordinary Shares upon the exercise of the
     Warrant;

(b)  this Warrant Agreement shall constitute full authority to the Company's
     directors who are charged with the duty of executing share certificates to
     execute and issue the necessary certificates for the Ordinary Shares which
     may be issued upon exercise of the Warrant;

(c)  the Company has all requisite legal and corporate power to execute and
     deliver this Warrant Agreement, to sell and issue the Ordinary Shares
     hereunder, and to carry out and perform its obligations under the terms of
     this Warrant Agreement;

(d)  all corporate action on the part of the Company, its directors and
     shareholders necessary for the authorization, execution, delivery and
     performance of this Warrant Agreement by the Company, the authorization,
     sale, issuance and delivery of the Ordinary Shares and the performance of
     the Company's obligations hereunder has been taken;

(e)  the Ordinary Shares, when issued in compliance with the provisions of this
     Warrant Agreement, will be validly issued, fully paid and free of any liens
     or encumbrances, and will be issued in compliance with all applicable laws;
     and

(f)  the issuance of the Ordinary Shares will not be subject to any preemptive
     rights, rights of first refusal or similar rights.

13.  REPRESENTATIONS AND WARRANTIES OF THE HOLDER

     The Holder hereby represents, warrants and agrees that:

(a)  The Holder is an "accredited investor," as such term is defined in Section
     501(a) of Regulation D of the Rules and Regulations promulgated under the
     Securities Act, under one or more of the categories as set forth on the
     attached Schedule 2 "Regulation D Qualification Statement."

(b)  The Holder is acquiring the Warrant and purchasing the securities which may
     be issued upon exercise of the Warrant solely for investment purposes, for
     the Holder's own account, not as a nominee or agent, and not with a view to
     the

                                      -15-

<PAGE>

     resale or distribution of any of such securities, except in accordance with
     applicable securities laws.

(c)  The Holder (i) was not organized or reorganized for the purpose of
     acquiring the Warrant and purchasing the securities which may be issued
     upon exercise of the Warrant, and (ii) is authorized, empowered and
     qualified to execute this Warrant Agreement and to make the commitment as
     herein contemplated.

(d)  The Holder has such knowledge and experience in financial and business
     matters that the Holder is capable of evaluating the merits and risks of
     the investment in the Warrant and the securities which may be issued upon
     exercise thereof and the Holder has made its own investment decision
     regarding the Warrant and the securities which may be issued upon exercise
     thereof based on the Holder's own knowledge and investigation of the
     Company and the Ordinary Shares.

(e)  The Holder acknowledges that all documents, records and books pertaining to
     the investment in the Company and requested by the Holder have been made
     available or delivered to the Holder.

(f)  The Holder has (i) been offered the opportunity to ask questions of and
     receive answers from the Company, or a person or persons acting on behalf
     of the Company, concerning the terms and conditions of the Warrant and the
     business of the Company, (ii) been furnished all other materials which the
     Holder considered relevant to an investment in the Ordinary Shares and
     (iii) been given the opportunity to perform due diligence. The Holder
     acknowledges that all such questions, if any, have been answered, and all
     due diligence (if any) has been performed, to the full satisfaction of the
     Holder.

(g)  The Holder has read this Warrant Agreement and, to the extent the Holder
     believed necessary, has discussed the representations, warranties and
     agreements that the undersigned makes by signing this Warrant Agreement and
     the applicable limitations upon the Holder's transfer or resale of its
     rights hereunder and the Ordinary Shares with its counsel.

(h)  The execution, delivery and performance by the Holder of this Warrant
     Agreement are within the powers of the Holder, have been duly authorized
     and will not constitute or result in a breach or default under or conflict
     with any order, ruling or regulation of any court or other tribunal or of
     any governmental commission or agency, or any agreement or other
     undertaking, to which the Holder is a party or by which the Holder is
     bound, and will not violate any provisions of the incorporation papers,
     by-laws, indenture of trust or partnership agreement, as may be applicable,
     of the Holder. This Warrant Agreement constitutes a legal, valid and
     binding obligation of the Holder, enforceable in accordance with its terms.

(i)  The Holder agrees to advise the Company promptly of any changes or
     inaccuracies in the information provided to the Company that may occur
     prior to

                                      -16-

<PAGE>

     the Expiration Time and to furnish supplementary information as may be
     appropriate.

14.  ENTIRE AGREEMENT

     This Warrant Agreement constitutes the entire agreement and understanding
     between the parties with respect to the subject matter of this Warrant
     Agreement and supersedes and extinguishes any prior drafts, agreements,
     undertakings, representations, warranties and arrangements of any nature
     whatsoever, whether or not in writing, relating to or in connection with
     this Warrant Agreement provided that nothing in this Warrant Agreement
     shall limit a party's liability for fraudulent misrepresentation.

15.  COUNTERPARTS

     This Warrant Agreement may be executed in any number of counterparts, each
     of which shall be deemed to be an original, and which together shall
     constitute one and the same Warrant Agreement. Unless otherwise provided in
     this Warrant Agreement, this Warrant Agreement shall become effective and
     be dated (and each counterpart shall be dated) on the date on which this
     Warrant Agreement (or a counterpart of this Warrant Agreement) is signed by
     the last of the parties to execute this Warrant Agreement or, as the case
     may be, a counterpart hereof. This Warrant Agreement may be executed by
     either party by the delivery by such party by facsimile of a copy of the
     signature page of this Warrant Agreement, duly executed by such party. Any
     copy of this Warrant Agreement so executed by facsimile shall be deemed to
     be an originally executed copy of this Warrant Agreement.

16.  NOTICES

     Any notice, demand or other communication given or made under or in
     connection with the matters contemplated by this Warrant Agreement shall be
     in writing in English and shall be delivered personally or sent by fax,
     reputable overnight courier or prepaid first class post (air mail if posted
     to or from a place outside the United Kingdom):

     In the case of the Company, to:

     Amarin Corporation plc
     7 Curzon Street
     London W1J 5HG
     England
     Fax:       +44 (0) 20 7499 9004
     Attention: Mr. Jonathan Lamb, General Counsel & Company Secretary

     In the case of [o], to:

     [o]

                                      -17-

<PAGE>

     [o]
     [o]
     [o]
     Fax:       [o]
     Attention: [o]

     (or such other address as a party may notify to the other by written
     notice) and shall be deemed to have been duly given or made as follows:

     (i)   if personally delivered or delivered by reputable overnight courier,
           upon delivery at the address of the relevant party on a business day
           in the destination location;

     (ii)  if sent by first class post, on the tenth business day in the
           destination location after date of posting;

     (iii) if sent by fax, when dispatched on a business day in the destination
           location;

     provided that if, in accordance with the above provision, any such notice,
     demand or other communication would otherwise be deemed to be given or made
     after 5.00 p.m. at the destination location such notice, demand or other
     communication shall be deemed to be given or made at 9.00 a.m. on the next
     business day in such location.

17.  THIRD PARTY RIGHTS

(a)  The Company's directors and officers and each other person, if any, who
     controls the Company within the meaning of Section 15 of the Securities Act
     (as defined in Section 7) (the "Third Parties") shall have the benefit of
     the rights conferred by Section 8(g) (the "Third Party Rights") which shall
     be enforceable by the Third Parties in accordance with the Contracts
     (Rights of Third Parties) Act 1999 (the "Third Parties Act"), subject to
     this Section 17. In the event of any conflict between the Third Parties Act
     (including, for the avoidance of doubt, any judicial interpretation of that
     Act) and the remainder of this Section 17, this Section 17 shall prevail.

(b)  The Company may exercise Third Party Rights in all respects on behalf of
     any Third Party at the Company's sole discretion as if the Company were
     such Third Party. All Third Party Rights (including, without limitation,
     enforcement rights) are exercisable against the Holder only indirectly,
     through the Company in accordance with this Section 17, and are not
     exercisable by any Third Party directly against the Holder other than with
     the Company's prior consent and then only to the extent permitted by such
     consent. Any such consent may be withheld at the Company's absolute
     discretion and may be given subject to such restrictions as the Company may
     impose at its absolute discretion. The terms of any such consent may be
     varied or waived by the Company at its absolute discretion.

                                      -18-

<PAGE>

(c)  The Company does not owe any duty to any Third Party or to any other person
     that is not a party to this Warrant Agreement, nor will the Company be
     liable to any Third Party or to any other such person for any act or
     omission of any kind or for any exercise of the Company's discretion in any
     way, in respect of any Third Party Rights or in respect of any other matter
     concerning or relating to this Warrant Agreement.

(d)  No term of this Warrant Agreement is enforceable by any person who is not a
     party to it, other than as stated above in this Section 17. Where
     applicable, words used in this Section 17 have the meanings that they have
     under the Third Parties Act.

(e)  This Warrant Agreement may be varied or amended only by written agreement
     between the Holder and the Company in accordance with Section 18 and
     without the need for any consent from any Third Party. This Warrant
     Agreement may also be terminated in accordance with its terms without the
     need for any consent from any Third Party.

18.  WAIVER; AMENDMENT

(a)  A waiver of any term, provision or condition of this Warrant Agreement
     shall be effective only if given in writing and signed by the waiving party
     and then only in the instance and for the purpose for which it is given.

(b)  No failure or delay on the part of any party in exercising any right, power
     or privilege under this Warrant Agreement shall operate as a waiver
     thereof, nor shall any single or partial exercise of any such right, power
     or privilege preclude any other or further exercise thereof or the exercise
     of any other right, power or privilege.

(c)  No breach of any provision of this Warrant Agreement shall be waived or
     discharged except with the express written consent of the Company and the
     Holder.

(d)  Save as provided in Sections 3 and 10, this Warrant Agreement may be varied
     or amended only by written agreement of the Company and the Holder.

19.  GOVERNING LAW

     This Warrant Agreement shall be governed by and construed in accordance
     with the laws of England.

EXECUTED by the parties hereto as a deed on the date first above written.

                                      -19-

<PAGE>

EXECUTED as a deed                              )
by AMARIN CORPORATION PLC                       )   Director:
and signed by two duly authorised               )
officers on its behalf                          )   Director/Secretary:

[EXECUTED and DELIVERED as a deed               )
by [o] in the presence of:                      )
                                                )

Signature of Witness:

Name of Witness:

Address of Witness:

Occupation of Witness:]

[EXECUTED and DELIVERED as a deed               )
by [o] as trustee of [insert name of trust]     )
in the presence of:                             )

Signature of Witness:

Name of Witness:

Address of Witness:

Occupation of Witness:]

[EXECUTED and DELIVERED as a                    )
deed by [o] as trustee of [insert name of       )
trust] and signed by two duly authorised        )
officers on its behalf]                         )

<PAGE>

                                                                      SCHEDULE 1

                               NOTICE OF EXERCISE

To:  Amarin Corporation plc

     (1) The undersigned hereby elects to purchase __________ Ordinary Shares of
Amarin Corporation plc pursuant to the terms of the Warrant Agreement dated [o]
2003 between Amarin Corporation plc and [o], and tenders herewith payment of the
purchase price in full.

     (2) Please issue a certificate or certificates representing said shares in
the name of the undersigned.

     (3) The undersigned represents that the aforesaid shares are being acquired
for the account of the undersigned for investment and not with a view to, or for
resale in connection with, the distribution thereof and that the undersigned has
no present intention of distributing or reselling such shares, except in
compliance with applicable laws.

Dated: _________________, 200

                                        ________________________________________
                                        [o]

                                        By: ____________________________________
                                            Name:
                                            Title:

<PAGE>

                                                                      SCHEDULE 2

                                  REGULATION D

                             QUALIFICATION STATEMENT

          The Holder qualifies as an "accredited investor" pursuant to
Regulation D under the Securities Act of 1933, as amended (the "Securities
Act"), as a result of its status as (check the appropriate description(s)):

_____________  1.   any bank as defined in Section 3(a)(2) of the Securities Act
                    or any savings and loan association or other institution as
                    defined in Section 3(a)(5)(A) of the Securities Act whether
                    acting in its individual or fiduciary capacity; any broker
                    dealer registered pursuant to Section 15 of the Securities
                    Exchange Act of 1934; any insurance company as defined in
                    Section 2(13) of the Securities Act; any investment company
                    registered under the Investment Company Act of 1940 or a
                    business development company as defined in Section 2(a)(48)
                    of that act; any Small Business Investment Company licensed
                    by the U.S. Small Business Administration under Section
                    301(c) or (d) of the Small Business Investment Act of 1958;
                    any plan established and maintained by a state, its
                    political subdivisions, or any agency or instrumentality of
                    a state or its political subdivisions, for the benefit of
                    its employees, if such plan has total assets in excess of
                    $5,000,000;

_____________  2.   a private business development company as defined in Section
                    202(a)(22) of the Investment Advisers Act of 1940;

_____________  3.   an organization described in Section 501(c)(3) of the
                    Internal Revenue Code, corporation, Massachusetts or similar
                    business trust, or partnership, not formed for the specific
                    purpose of acquiring the securities offered, with total
                    assets in excess of $5,000,000;

_____________  4.   a trust with total assets greater than $5,000,000, not
                    formed for the purpose of acquiring the securities offered,
                    whose purchase is directed by a person who has such
                    knowledge and experience in financial and business matters
                    that it is capable of evaluating the merits and risks of the
                    investment;

<PAGE>

_____________  5.   an employee benefit plan within the meaning of Title I of
                    the Employee Retirement Income Security Act of 1974, if any
                    of the following apply:

_____________       (i)   the employee benefit plan has total assets in excess
                          of $5,000,000;

_____________       (ii)  the investment decision is made by a plan fiduciary,
                          as defined in Section 3(21) of such Act, which is
                          either a bank, savings and loan association, insurance
                          company, or registered investment adviser; or

_____________       (iii) the plan is a self-directed plan in which the
                          investment decisions are made solely by persons who
                          are accredited investors. (Please put an "*" in the
                          appropriate description(s) to indicate how the
                          person(s) making investment decisions are
                          "accredited"); or

_____________  6.   a natural person whose individual net worth, or joint net
                    worth with his or her spouse, exceeds US$1,000,000;

_____________  7.   a natural person who had an individual income in excess of
                    US$200,000 in each of the two most recent years, or joint
                    income with his or her spouse in excess of US$300,000 in
                    each of those years, and who has a reasonable expectation of
                    reaching the same income level in the current year; or

_____________  8.   an entity in which all of the equity owners are "accredited
                    investors" under any one or more of the categories specified
                    in subparagraphs 1 through 7 above.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]